Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 26.43%2.57B | 62.14%2.56B | 66.82%2.37B | 28.46%7.88B | 53.05%2.85B | 31.82%2.03B | 7.61%1.58B | 12.28%1.42B | 18.12%6.14B | 21.78%1.87B |
| Cost of revenue | 31.76%6.05B | 16.10%4.59B | ||||||||
| Gross profit | 18.66%1.83B | 24.55%1.55B | ||||||||
| Operating expense | 23.72%2.23B | 67.20%2.26B | 70.33%2.14B | 12.26%1.24B | 65.01%2.56B | 27.46%1.8B | 1.89%1.35B | 9.57%1.26B | 20.87%1.11B | 20.25%1.55B |
| Selling and administrative expenses | ---- | ---- | ---- | 9.88%795.22M | ---- | ---- | ---- | ---- | 10.57%723.73M | ---- |
| -Selling and marketing expense | ---- | ---- | ---- | 6.89%195.73M | ---- | ---- | ---- | ---- | 8.47%183.12M | ---- |
| -General and administrative expense | ---- | ---- | ---- | 10.89%599.49M | ---- | ---- | ---- | ---- | 11.30%540.61M | ---- |
| Other operating expenses | 25.69%2.35B | 61.19%2.33B | 68.77%2.2B | 16.79%445.68M | 54.47%2.67B | 30.68%1.87B | 7.12%1.45B | 9.55%1.3B | 46.79%381.61M | 21.63%1.73B |
| Total other operating income | 81.00%116.08M | -26.40%68.34M | 21.88%50.95M | 23.21%313.41M | -36.29%114.62M | 349.35%64.14M | 326.01%92.85M | 8.93%41.8M | --254.37M | 35.01%179.93M |
| Operating profit | 48.10%334.38M | 31.91%299.21M | 39.18%222.88M | 34.72%593.47M | -5.73%297.28M | 81.39%225.79M | 61.81%226.83M | 39.37%160.13M | 34.86%440.53M | 29.89%315.34M |
| Net non-operating interest income (expenses) | 476.90%26.35M | 76.36%-2.27M | 48.43%-13.41M | 62.21%-46.01M | 202.23%24.76M | 116.28%4.57M | 34.19%-9.6M | -541.43%-26.01M | -68.35%-121.77M | -3,957.12%-24.22M |
| Non-operating interest income | 23.25%123.85M | 12.61%97.29M | 29.19%76.59M | 58.88%310.45M | 59.40%116.68M | 62.78%100.48M | 35.40%86.4M | 1.59%59.29M | 57.78%195.4M | 18.80%73.2M |
| Non-operating interest expense | 1.65%97.5M | 3.72%99.56M | 5.52%90M | 13.12%361.37M | -5.65%91.92M | 6.84%95.92M | 22.45%95.99M | 36.67%85.3M | 63.02%319.46M | 56.59%97.42M |
| Total other finance cost | ---- | ---- | ---- | -114.52%-4.9M | ---- | ---- | ---- | ---- | -1,199.04%-2.29M | ---- |
| Net investment income | -39.12%91.97M | 47.28%151.08M | ||||||||
| Gain(Loss) on financial instruments designated as cash flow hedges | 1,546.45%13.68M | -23.48%831K | ||||||||
| Gain(Loss) on derecognition of available-for-sale financial assets | 16.53M | 0 | ||||||||
| Income from associates and other participating interests | -49.82%118.28M | -26.59%102.1M | 2.12%96.26M | 61.73%643.12M | 115.93%174.08M | 50.39%235.7M | 79.29%139.08M | 13.94%94.27M | -4.69%397.65M | -1.75%80.62M |
| Special income (charges) | 22.73%-2.62M | 79.92%-3.07M | 4.89%-1.61M | 788.15%29.02M | 88.64%-2.41M | 36.65%-3.4M | -9,567.09%-15.27M | -10.19%-1.7M | -74.64%3.27M | 23.71%-21.24M |
| Less:Impairment of capital assets | ---- | ---- | ---- | 56.48%-8.79M | ---- | ---- | ---- | ---- | ---20.18M | ---- |
| Less:Other special charges | ---- | ---- | ---- | -262.91%-38.14M | ---- | ---- | ---- | ---- | 78.63%-10.51M | ---- |
| Less:Write off | -22.73%2.62M | -79.92%3.07M | -4.89%1.61M | -34.70%17.91M | -88.64%2.41M | -36.65%3.4M | 9,567.09%15.27M | 10.19%1.7M | -24.45%27.43M | -23.71%21.24M |
| Other non-operating income (expenses) | 49.49%182.01M | 28.89%121.76M | ||||||||
| Income before tax | 2.97%476.38M | 16.11%395.97M | 34.15%304.11M | 53.40%1.52B | 40.86%493.7M | 86.71%462.66M | 67.99%341.04M | 18.05%226.69M | 9.25%993.34M | 18.26%350.49M |
| Income tax | 63.44%88.56M | 48.85%66.37M | 88.76%67.47M | 76.25%242.67M | 224.37%107.32M | 33.66%54.18M | 44.78%44.59M | 7.46%35.75M | -16.22%137.69M | -55.42%33.08M |
| Net income | -5.06%387.82M | 11.18%329.61M | 23.93%236.64M | 49.72%1.28B | 21.73%386.39M | 97.08%408.48M | 72.14%296.46M | 20.27%190.95M | 14.87%855.66M | 42.87%317.41M |
| Net income continuous operations | -5.06%387.82M | 11.18%329.61M | 23.93%236.64M | 49.72%1.28B | 21.73%386.39M | 97.08%408.48M | 72.14%296.46M | 20.27%190.95M | 14.87%855.66M | 42.87%317.41M |
| Noncontrolling interests | 53.34%49.68M | 118.03%56.66M | 146.19%46.08M | 8.69%128.03M | -0.96%50.92M | 20.18%32.4M | 16.59%25.99M | 9.30%18.72M | 54.46%117.79M | 196.29%51.41M |
| Net income attributable to the company | -10.09%338.14M | 0.92%272.95M | 10.64%190.55M | 56.27%1.15B | 26.12%335.47M | 108.58%376.08M | 80.39%270.47M | 21.60%172.23M | 10.36%737.87M | 29.87%266M |
| Preferred stock dividends | -50.00%12.83M | 0 | -50.00%12.83M | 0.00%51.33M | 0 | 0.00%25.67M | 0 | 25.67M | -0.00%51.33M | 0 |
| Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income attributable to common stockholders | -7.16%325.31M | 0.92%272.95M | 21.26%177.72M | 60.48%1.1B | 26.12%335.47M | 126.61%350.41M | 80.39%270.47M | 3.47%146.56M | 11.22%686.54M | 29.87%266M |
| Gross dividend payment | ||||||||||
| Basic earnings per share | -8.33%0.0484 | -0.97%0.0407 | 17.62%0.0267 | 44.64%0.1672 | 14.58%0.0503 | 102.30%0.0528 | 61.81%0.0411 | 14.65%0.0227 | 9.89%0.1156 | 25.79%0.0439 |
| Diluted earnings per share | -7.98%0.0484 | -0.25%0.0407 | 19.20%0.0267 | 48.75%0.1672 | 17.80%0.0503 | 109.56%0.0526 | 62.55%0.0408 | 14.87%0.0224 | 9.23%0.1124 | 23.77%0.0427 |
| Dividend per share | 0 | 0 | 14.29%0.04 | 0.00%0.055 | 0 | 0.00%0.02 | 0 | 0.00%0.035 | 57.14%0.055 | 0 |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.